Compare FedEx Corporation (FDX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Sana Biotechnology Inc — how do they compare? FedEx Corporation trades at $318.47 (market cap $74.78B), while Sana Biotechnology Inc trades at $3.14 (market cap $987.94M). The key difference: FedEx Corporation is far larger — about 75.7× Sana Biotechnology Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FDX | SANA | |
|---|---|---|
Market Cap | $74.78B | $987.94M |
Sector | Industrials | Health |
52-Week High | $338.75 | $5.92 |
52-Week Low | $174.81 | $2.68 |
Enterprise Value | $104.42B | $962.13M |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $316.24, up 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows steady revenue near $88B and net income of $4.09B in 2025, supported by a P/E of 16.9 and strong analyst consensus. Recent developments include the sale of FedEx Supply Chain for $1.4B and a $4.15B debt tender offer, enhancing financial flexibility.
The outlook is mixed: cost-cutting initiatives and strategic divestitures provide upside, but competitive pressures from Amazon and soft shipping demand pose risks. With 57% of analysts rating it Buy and a $360.27 price target, the stock offers potential appreciation if margin recovery aligns with guidance, though execution remains key.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
